Skip to main content

Advertisement

SpringerLink
Log in

The Relationship Between Cholesterol and Stroke

Implications for Antihyperlipidaemic Therapy in Older Patients

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Various studies on the relationship between serum cholesterol level and the risk of stroke have been published recently. Subsequent reviews have extrapolated information on stroke from the clinical trials originally aimed at lowering cholesterol for the primary and secondary prevention of myocardial infarction (MI) in middle-aged patients. We have reviewed the epidemiological knowledge on the relationship between serum cholesterol levels and stroke, and also focused on possible reduction of the risk of stroke with hydroxymethyglutaryl coenzyme A (HMG-CoA) reductase inhibitor treatment. Possible benefits from such therapy are particularly relevant for the elderly population which is at particularly high risk for stroke.

The effects of serum cholesterol levels on the risk for haemorrhagic and ischaemic stroke have been evaluated. Indirect epidemiological evidence indicates that serum levels of total cholesterol and its subfractions are determinants of stroke, but their associations are relatively weak. When exploring the possible association of serum cholesterol levels with the increased risk of stroke with aging, we concluded that, as in younger adults, elevated total cholesterol and decreased high density lipoprotein-cholesterol levels predispose to ischaemic stroke in the elderly. The mechanism through which serum cholesterol levels increase stroke risk is based on its actions on the artery walls.

Indirect evidence suggests that the reduction in the stroke risk with HMG-CoA reductase inhibitors is larger than would be expected with reduction of elevated serum cholesterol level alone. Therefore, antioxidant and endothelium-stabilising properties of HMG-CoA reductase inhibitors may contribute in reducing the risk of stroke in recipients.

Lowering high serum cholesterol with HMG-CoA reductase inhibitors has been beneficial in the primary and secondary prevention of MI. No trials have specifically tested the effect of cholesterol lowering with HMG-CoA reductase inhibitors on stroke occurrence. High serum cholesterol levels are a risk factor for ischaemic stroke, although the risk imparted is lower than that for MI. Although the relative risk of stroke associated with elevated serum cholesterol levels is only moderate, its population attributable risk is high given the increase in the elderly population worldwide.

The effect of cholesterol reduction with HMG-CoA reductase inhibitors on prevention of ischaemic stroke should be evaluated in prospective, randomised, placebo-controlled trials in the elderly. The tolerability of lipid-lowering drugs in the elderly and the cost effectiveness of primary prevention of stroke using lipid-lowering drugs also needs to be assessed in the elderly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Thorn T. Stroke mortality trends: an international perspective. Ann Epidemiol 1993; 3: 509–18

    Google Scholar 

  2. Thorvaldsen P, Kuulasmaa K, Rajakangas A-M, et al. Stroke trends in the WHO MONICA Project. Stroke 1997; 28: 500–6

    PubMed  CAS  Google Scholar 

  3. American Heart Association. Stroke facts. Dallas (TX): American Heart Association, 1988

    Google Scholar 

  4. Scandinavian Simvastatin Survival Study Group. Baseline cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345: 1274–5

    Google Scholar 

  5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001–9

    PubMed  CAS  Google Scholar 

  6. Wolf PA, Kannel WB, Verter J. Current status of risk factors for stroke. Neurol Clin 1983; 1: 317–43

    PubMed  CAS  Google Scholar 

  7. Harmsen P, Tsipogianni A, Wilhelmsen L. Stroke incidence rates were unchanged, while fatality rates declined, during 1971–1987 in Göteborg, Sweden. Stroke 1992; 23: 1410–5

    PubMed  CAS  Google Scholar 

  8. Reed DM. The paradox of high risk of stroke in populations with low risk of coronary heart disease. Am J Epidemiol 1990; 131: 579–88

    PubMed  CAS  Google Scholar 

  9. Iribarren C, Reed DM, Burchfiel CM, et al. Serum total cholesterol and mortality: confounding and risk modification in Japanese-American men. JAMA 1995; 273: 1926–32

    PubMed  CAS  Google Scholar 

  10. Iribarren C, Jacobs D, Sadler M, et al. Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? The Kaiser Permanente Medical Care Program. Stroke 1996; 27: 1993–8

    PubMed  CAS  Google Scholar 

  11. Postiglione A, Napoli C. Hyperlipidaemia and atherosclerotic cerebrovascular disease. Curr Opin Lipidol 1995; 6: 236–42

    PubMed  CAS  Google Scholar 

  12. Ueda K. Epidemiological study on cerebrovascular disease in a Japanese community, Hysayama. J Epidemiol 1992; 2 Suppl.: 105–10

    Google Scholar 

  13. Eastern Stroke and Coronary Heart Disease Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 1998; 352: 1801–7

    Google Scholar 

  14. Ko GT, Chan JC, Woo J, et al. The effect of age on the cardiovascular risk factors in Chinese women. Int J Cardiol 1997; 61: 221–7

    PubMed  CAS  Google Scholar 

  15. Heng CK, Saha N, Tay JS, et al. Plasma lipids and lipoprotein(a) levels in the Chinese from China and Singapore. Ann Acad Med Singapore 1997; 26: 303–7

    PubMed  CAS  Google Scholar 

  16. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet 1995; 346: 1647–53

    Google Scholar 

  17. Ueshima H, Iida M, Shimamoto T, et al. Multivariate analysis of risk factors for stroke: eight year follow-up study of farming villages in Akita, Japan. Prev Med 1980; 9: 722–40

    PubMed  CAS  Google Scholar 

  18. Kagan A, Popper JS, Rhoads GG. Factors related to stroke incidence in Hawaii Japanese men. Stroke 1980; 11: 14–20

    PubMed  CAS  Google Scholar 

  19. Lindenstrom ES, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglyceride on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ 1994; 309: 11–5

    PubMed  CAS  Google Scholar 

  20. Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Int Med 1992; 152: 1490–500

    CAS  Google Scholar 

  21. Di Mascio R, Marchioli R, Vitullo F, et al. Serum cholesterol and risk of ischemic stroke: results from a case-control study. Prev Med 1995; 24: 128–33

    PubMed  Google Scholar 

  22. Benfante R, Yano K, Hwang LJ, et al. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men: implications of shared risk. Stroke 1994; 25: 814–20

    PubMed  CAS  Google Scholar 

  23. Haheim LL, Holme I, Hjerman I, et al. Risk factors of stroke incidence and mortality: a 12-follow-up of the Oslo study. Stroke 1993; 24: 1484–9

    PubMed  CAS  Google Scholar 

  24. Tuomilehto J, Rastenyte D, Jousilahti P, et al. Diabetes mellitus as a risk factor for death from stroke: prospective study of the middle-aged Finnish population. Stroke 1996; 27: 825–32

    PubMed  CAS  Google Scholar 

  25. Palmer A, Bulpitt C, Beevers G, et al. Risk factors for ischaemic heart disease and stroke mortality in young and old hypertensive patients. J Hum Hypertens 1995; 9: 695–7

    PubMed  CAS  Google Scholar 

  26. Konishi M, Iso H, Komachi Y, et al. Association of serum total cholesterol, different types of stroke, and stenosis distribution of cerebral arteries: the Akita Pathology Study. Stroke 1993; 24: 954–64

    PubMed  CAS  Google Scholar 

  27. American Heart Association. Nutrition Committee advisory. Blood cholesterol and stroke. Dallas (TX): American Heart Association, 1996

    Google Scholar 

  28. Kaste M, Koivisto P. Risk of brain infarction in familial hypercholesterolemia. Stroke 1988; 19: 1097–100

    PubMed  CAS  Google Scholar 

  29. Vartianen E, Sarti C, Tuomilehto J, et al. Do changes in cardiovascular risk factors explain changes in mortality from stroke in Finland? BMJ 1995; 12: 391–9

    Google Scholar 

  30. Dyker AG, Weir CJ, Kennedy RL. Influence of cholesterol on survival after stroke: retrospective study. BMJ 1997; 314: 1584–8

    PubMed  CAS  Google Scholar 

  31. Ryder REJ, Hayes TM, et al. How soon after myocardial infarction should plasma lipids be assessed? BMJ 1984; 209: 1651–3

    Google Scholar 

  32. Marini C, Di Napoli M, Di Gianfilippo G, et al. High stroke incidence in the community-based L’Aquila stroke registry: two-year results [abstract]. Neurology 1997; 48Suppl. 1: A159

    Google Scholar 

  33. Skalabrin EJ, Santalucia P, Marini C, et al. Prevalence and comorbidity of chronic atrial fibrillation in cerebral ischemia [abstract]. Cerebrovasc Dis 1997; 7Suppl. 4: 40

    Google Scholar 

  34. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study. Stroke 1991; 22: 983–8

    PubMed  CAS  Google Scholar 

  35. Cerebral Embolism Task Force. Cardiogenic brain embolism: the second report of the Cerebral Embolism Task Force [published erratum appears in Arch Neurol 1989; 46 (7)]. Arch Neurol 1989; 46: 727–43

    Google Scholar 

  36. Britton M, Gustafsson C. Non-rheumatic atrial fibrillation as a risk factor for stroke. Stroke 1985; 16: 182–7

    PubMed  CAS  Google Scholar 

  37. Kaarisalo MM, Immonen-Räihä P, Marttila RJ, et al. Atrial fibrillation and stroke: mortality and causes of death after the first acute ischemic stroke. Stroke 1997; 28: 311–5

    PubMed  CAS  Google Scholar 

  38. Sandercock P, Bamford J, Dennis M, et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire Community Stroke Project). BMJ 1992; 305: 1460–5

    PubMed  CAS  Google Scholar 

  39. Wolf PA, Kannel WB, McGee DL, et al. Duration of atrial fibrillation and imminence of stroke: the Framingham study. Stroke 1983; 14: 664–7

    PubMed  CAS  Google Scholar 

  40. Friedman PJ. Atrial fibrillation after stroke in the elderly. Stroke 1991; 22: 209–14

    PubMed  CAS  Google Scholar 

  41. Censori B, Camerlingo M, Casto L, et al. Prognostic factors in first-ever stroke in the carotid artery territory seen within 6 hours after onset. Stroke 1993; 24: 532–5

    PubMed  CAS  Google Scholar 

  42. Sacks FM, Moyé LA, Davis BR, et al. Relationship between plasma LDL concentration during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation 1998; 97: 1446–52

    PubMed  CAS  Google Scholar 

  43. Stein EA, Davidson MH, Dobs AS, et al. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. Am J Cardiol 1998; 82: 311–6

    PubMed  CAS  Google Scholar 

  44. Dart A, Jerum G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997; 80: 39–44

    PubMed  CAS  Google Scholar 

  45. Corti M, Barbato G-M, Baggio G. Lipoprotein alterations and atherosclerosis in the elderly. Curr Opin Lipidol 1997; 8: 236–41

    PubMed  CAS  Google Scholar 

  46. Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality: a 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. Stroke 1997; 28: 83–7

    PubMed  CAS  Google Scholar 

  47. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol: modification of low-density lipoprotein that increases its atherogenicity. N Engl J Med 1989; 320: 915–24

    PubMed  CAS  Google Scholar 

  48. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657–71

    PubMed  CAS  Google Scholar 

  49. Ettinger Jr WH, Verdery RB, Wahl PW, et al. High density lipoprotein cholesterol subfractions in older people. J Gerontology 1994; 49: 116–22

    Google Scholar 

  50. Murai A, Miyahara T, Fujimoto N, et al. Lp (a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986; 59: 199–204

    PubMed  CAS  Google Scholar 

  51. Zenker G, Koeltringer P, Bone G, et al. Lipoprotein (a) as a strong indicator of cerebrovascular disease. Stroke 1986; 17: 942–5

    PubMed  CAS  Google Scholar 

  52. Nagayama M, Shinohara Y, Nagayama T. Lipoprotein (a) and ischemic heart disease in young adults. Stroke 1994; 25: 74–8

    PubMed  CAS  Google Scholar 

  53. Pedro-Bodet J, Senti M, Nogues X, et al. Lipoprotein and apoprotein profile in men with ischemic stroke: role of lipoprotein (a), triglyceride-rich lipoproteins and apolipoprotein E polymorphism. Stroke 1992; 23: 1557–62

    Google Scholar 

  54. Watts GF, Mazwekiewicz JC, Tonge K, et al. Lipoprotein (a) as a determinant of severity of angiographically defined carotid atherosclerosis. Q J Med 1995; 88: 321–6

    CAS  Google Scholar 

  55. Simons L, Friedlander Y, Simons J, et al. Lipoprotein (a) is not associated with coronary heart disease in the elderly: cross-sectional data from the Dubbo study. Atherosclerosis 1993; 99: 2540–4

    Google Scholar 

  56. Kario K, Matsuo T, Imiya M, et al. Close relation between lp(a) and atherothrombotic disease in Japanese subjects >75 years of age. Am J Cardiol 1994; 73: 1187–90

    PubMed  CAS  Google Scholar 

  57. Schwartz C, Valente A, Sprague E. A modern view of athero-genesis. Am JCardiol 1993; 71: 9–14B

    Google Scholar 

  58. Steinberg D, Witztum JL. Lipoproteins and atherogenesis. JAMA 1990; 264: 3047–52

    PubMed  CAS  Google Scholar 

  59. Navab M, Fogelman AM, Berliner JA, et al. Pathogenesis of atherosclerosis. Am J Cardiol 1995; 76(9): 18–23C

    Google Scholar 

  60. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 425–30

    Google Scholar 

  61. Duverger N. In vivo delivery/effect on vascular pathologies [abstract]. XII International Symposium on Drugs Affecting Metabolism; 1998 May 30–Jun 3; Florence, 12

  62. Woo J, Lau E, Lam CWK, et al. Hypertension, lipoprotein (a), and apoprotein A-l as risk factors for stroke in the Chinese. Stroke 1991; 22: 203–8

    PubMed  CAS  Google Scholar 

  63. Okada T, Sato Y, Yamzaki T, et al. Lipoprotein (a) and apolipoprotein A-l and B in schoolchildren whose grandparents had coronary and cerebrovascular events: a preliminary study of 12–13 year old Japanese children. Acta Ped Jpn 1995; 37: 582–7

    CAS  Google Scholar 

  64. Shinozaki K, Naritomi H, Shimizu T, et al. Role of insulin resistance associated with compensatory hyperinsulinemia in ischemic stroke. Stroke 1996; 27: 37–43

    PubMed  CAS  Google Scholar 

  65. Makita Z, Yanagisawa K, Kuwajima S, et al. The role of advanced glycosilation end-products in the pathogenesis of atherosclerosis. Nephrol Dial Transplant 1996; 11Suppl. 5: 31–3

    PubMed  CAS  Google Scholar 

  66. Courdec R, Mahieux F, Bailleul S, et al. Prevalence of apolipo-protein E phenotypes in ischemic cerebrovascular disease: a case-control study. Stroke 1993; 24: 661–4

    Google Scholar 

  67. Kessler C, Spitzer C, Stauske D, et al. The apolipoprotein E and beta-fibrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease. Athero-scler Thromb Vase Biol 1997; 17: 2880–4

    CAS  Google Scholar 

  68. Kuusisto J, Mykkänen L, Kervinen K, et al. Apolipoprotein E4 phenotype is not an important risk factor for coronary heart disease or stroke in elderly subjects. Atheroscler Thromb Vase Biol 1995; 15: 1280–6

    CAS  Google Scholar 

  69. Alberts M, Graffagnino C, McClenny C, et al. ApoE genotype and survival from intracerebral hemorrhage [letter]. Lancet 1995; 346: 575

    PubMed  CAS  Google Scholar 

  70. Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation 1979; 60: 427–38

    Google Scholar 

  71. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels, among US adults: the National Health and Nutrition Examination Surveys. JAMA 1993; 269: 3002–8

    PubMed  CAS  Google Scholar 

  72. Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994; 272: 1335–40

    PubMed  CAS  Google Scholar 

  73. Zureik M, Coubon D, Ducimetière P. Decline in serum total cholesterol and the risk of death from cancer. Epidemiology 1997; 8: 137–43

    PubMed  CAS  Google Scholar 

  74. Weverling-Rijnsburger AWE, Blauw GJ, Lagaay AM, et al. Total cholesterol and risk of mortality in the oldest old. Lancet 1997; 350: 1119–23

    PubMed  CAS  Google Scholar 

  75. Corti M-C, Guralnik GM, Salive ME, et al. Clarifying the direct relationship of total cholesterol with coronary heart disease mortality in older persons. Ann Intern Med 1997; 126: 753–60

    PubMed  CAS  Google Scholar 

  76. Ettinger WH, Wahl PW, Kuller LH, et al. Lipoprotein lipids in older people: results from the Cardiovascular Health Study. Circulation 1992; 86: 858–69

    PubMed  CAS  Google Scholar 

  77. Wallace RB, Colsher PL. Blood lipid distributions in older persons: prevalence and correlates of hyperlipidemia. Ann Epidemiol 1992; 2(1-2): 15–21

    PubMed  CAS  Google Scholar 

  78. Malenka D, Baron J. Cholesterol and coronary heart disease: the importance of patient-specific attributable risk. Arch Intern Med 1988; 148: 2247–52

    PubMed  CAS  Google Scholar 

  79. Griffin BA. Lipoprotein atherogenecity: an overview of current mechanisms. Proc Nutr Soc 1999; 58(1): 165–9

    Google Scholar 

  80. Brown B, Zhao X, Sacco D, et al. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 993; 87: 1781–91

  81. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481–7

    PubMed  CAS  Google Scholar 

  82. Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke 1997; 28: 2315–20

    PubMed  CAS  Google Scholar 

  83. Tell GS, Crouse JR, Fuberg CD. Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis: a review. Stroke 1988; 19: 423–30

    PubMed  CAS  Google Scholar 

  84. Napoli C, Witztum JL, de Nigris F, et al. Intracranial arteries of human fetuses are more resistant to hypercholesterolemia-induced fatty streak formation than extracranial arteries. Circulation 1999; 99: 2003–10

    PubMed  CAS  Google Scholar 

  85. Heiss G, Sharett AR, Barnes R, et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991; 134: 250–6

    PubMed  CAS  Google Scholar 

  86. Napoli C, D’Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimai accumulation of LDL and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997; 100: 2680–90

    PubMed  CAS  Google Scholar 

  87. Chui DH, Marotta E, Rao ML, et al. Cholesterol-rich LDL perfused at physiological LDL-cholesterol concentration induces platelet aggregation and PAF-acetylhydrolase activation. Biomed Pharmacother 1991; 45: 37–42

    PubMed  CAS  Google Scholar 

  88. Simonsen U, Ehrnrooth E, Gerdes LU, et al. Functional properties in vitro of systemic small arteries from rabbits fed a cholesterol-rich diet for 12 weeks. Clin Sci 1991; 80: 119–29

    PubMed  CAS  Google Scholar 

  89. Mikhalidis DP, Wierzbicki AS, Lumb PJ, et al. Atorvastatin reduces LDL-cholesterol but has unpredictable effects on lipoprotein (a) [abstract]. XII International Symposium on Drugs Affecting Metabolism; 1998 May 30–Jun 3; Florence, 12

  90. Atalar E, Yildirir A, Kaaranfil A, et al. Simvastatin therapy decreases serum estrogen and DHEA-S levels significantly in hyperlipidemic patients with coronary heart disease [abstract]. XII International Symposium on Drugs Affecting Metabolism; 1998 May 30–Jun 3; Florence, 56

  91. Ryu JE, Howard G, Craven TE, et al. Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects. Stroke 1992; 23: 823–8

    PubMed  CAS  Google Scholar 

  92. Hochgraf E, Levy Y, Aviram M, et al. Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolemic patients. Metabolism 1997; 43: 11–7

    Google Scholar 

  93. Atkins D, Psaty BM, Koepsell TD, et al. Cholesterol reduction and the risk of stroke in men: a meta-analysis of randomized, controlled trials. Ann Intern Med 1993; 119: 136–45

    PubMed  CAS  Google Scholar 

  94. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGCoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med 1998; 128(2) 89–95

    PubMed  CAS  Google Scholar 

  95. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995; 92: 2419–25

    PubMed  CAS  Google Scholar 

  96. Herbert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997; 278: 313–21

    Google Scholar 

  97. Blauw GJ, Lagaay AM, Smelt AHM, et al. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997; 28: 946–50

    PubMed  CAS  Google Scholar 

  98. Crouse III JR, Byington RP, Hoen HM, et al. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997; 157: 1305–10

    PubMed  CAS  Google Scholar 

  99. Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol And Recurrent Events (CARE) study. Circulation 1999; 99: 216–3

    PubMed  CAS  Google Scholar 

  100. Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57

    Google Scholar 

  101. Shephered J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–7

    Google Scholar 

  102. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528–40

    PubMed  CAS  Google Scholar 

  103. Furberg CD, Adams HP, Applegate WB, et al., for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90: 1679–87

    PubMed  CAS  Google Scholar 

  104. Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media tickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996; 101: 627–34

    PubMed  CAS  Google Scholar 

  105. Hodis HN, Mack WJ, Dunn M, et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 1997; 95: 2022–6

    PubMed  CAS  Google Scholar 

  106. Byington RP, Fuberg CD, Crouse III JR, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995; 76: 54–9C

    Google Scholar 

  107. Salonen R, Nyssonen K, Porkkala-Sarataho E, et al. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 1995; 76: 34–9C

    Google Scholar 

  108. Guijarro C, Egido J. Modulation of the mevalonate pathway: potential mechanisms of vascular protection by HMG-CoA reductase inhibitors independent of cholesterol lowering. J Cardiovasc Risk 1998; 7: 29–35

    Google Scholar 

  109. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1993; 362: 801–9

    Google Scholar 

  110. Massy ZA, Keane WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet 1996; 347: 102–3

    PubMed  CAS  Google Scholar 

  111. Sinensky M, Lutz R. The prenylation of proteins. Bioessays 1992; 14: 25–31

    PubMed  CAS  Google Scholar 

  112. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 425–30

    Google Scholar 

  113. Corsini A, Mazzotti M, Raitieri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993; 101: 117–25

    PubMed  CAS  Google Scholar 

  114. Van Vliet AK, van Thiel GC, Huisman RH, et al. Different effects of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim Biophys Acta 1995; 1254: 105–11

    PubMed  Google Scholar 

  115. Quinn MT, Parthasarathy S, Fong LG, et al. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A 1987; 84: 2995–8

    PubMed  CAS  Google Scholar 

  116. Terkeltraub R, Solan J, Barry M, et al. Role of mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells. J Leukoc Biol 1994; 55: 749–55

    Google Scholar 

  117. Guijarro C, Keane WF. Effects of lipids in the pathogenesis of progressive renal failure: role of HMG-CoA reductase inhibitors in the prevention of glomerulosclerosis. Miner Electrolyte Metab 1996; 22: 147–52

    PubMed  CAS  Google Scholar 

  118. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and potential mechanisms. N Engl J Med 1995; 332: 512–21

    PubMed  CAS  Google Scholar 

  119. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. Am J Cardiol 1995; 76: 24–33C

    Google Scholar 

  120. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079–82

    PubMed  CAS  Google Scholar 

  121. Stowe NT, Inman SR, Tapolyai M, et al. Lovastatin has direct renal hemodynamic effects in a rodent model. J Urol 1996; 156: 249–52

    PubMed  CAS  Google Scholar 

  122. Rossouw J. Lipid-lowering interventions in the angiographic trials. Am J Cardiol 1995; 76: 86–92C

    Google Scholar 

  123. Loh E, Sutton MJ, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997; 336: 251–7

    PubMed  CAS  Google Scholar 

  124. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9

    Google Scholar 

  125. Shear CL, Franklin FA, Stinnett S, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation 1992; 85: 1293–303

    PubMed  CAS  Google Scholar 

  126. Bach LA, Cooper ME, O’Brien RC, et al. The use of simvastatin, an HMGCoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis. J Am Geriatr Soc 1990; 38: 10–4

    PubMed  CAS  Google Scholar 

  127. Pedersen T, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156: 2085–92

    PubMed  CAS  Google Scholar 

  128. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol 1994; 74: 667–73

    PubMed  CAS  Google Scholar 

  129. Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 1997: 79: 1475–81

    PubMed  CAS  Google Scholar 

  130. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–64

    Google Scholar 

  131. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–64

    PubMed  CAS  Google Scholar 

  132. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized controlled trial. JAMA 1997; 349: 594–8

    Google Scholar 

  133. Tuomilehto J, Rastenyte D, Birkenhäger W, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677–84

    PubMed  CAS  Google Scholar 

  134. Evers SMAA, Engel GL, Ament AJHA. Cost of stroke in The Netherlands from a societal perspective. Stroke 1997; 28: 1375–81

    PubMed  CAS  Google Scholar 

  135. Meerding WJ, Bonneux L, Polder JJ, et al. Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. BMJ 1998; 317: 111–5

    PubMed  CAS  Google Scholar 

  136. Bergman L, Meulen JHP, Limburg M, et al. Costs of medical care after first-ever stroke in the Netherlands. Stroke 1996; 26: 1830–6

    Google Scholar 

  137. Malmgren R, Bamford J, Warlow C, et al. Projecting the number of first-ever strokes and patients newly handicapped by stroke in England and Wales. BMJ 1989; 289: 656–60

    Google Scholar 

  138. Haidinger G, Waldhoer, Tuomilehto J, et al. Assessment of costs related to hospitalization of stroke patients in Austria for 1992 and prospective costs for the year 2010. Cerebrovasc Dis 1997; 7: 163–7

    Google Scholar 

  139. Dobkin B. The economic impact of stroke. Neurology 1995; 45 (2 Suppl. 1): S6–9

    PubMed  CAS  Google Scholar 

  140. Leibson CL, Hu T, Brown RD, et al. Utilization of acute care services in the year before and after first stroke: a population-based study. Neurology 1996; 46: 861–9

    PubMed  CAS  Google Scholar 

  141. Malcom LA, Kawachi I, Jackson R, et al. Is the pharmacological treatment of mild to moderate hypertension cost effective in stroke prevention? N Z Med J 1988; 101: 167–71

    Google Scholar 

  142. Hankey GJ. Impact of treatment of people with transient ischaemic attacks on stroke incidence and public health. Cerebrovascular Dis 1996; 6Suppl. 1: 26–33

    Google Scholar 

  143. Kaste M, Fogelholm R, Rissanen A. Economic burden of stroke and the evaluation of new therapies. Public Health 1998; 112: 103–12

    PubMed  CAS  Google Scholar 

  144. Beech R, Rudd AG, Tilling K, et al. Economic consequences of early impatient discharge to community based rehabilitation for stroke in an inner-London teaching hospital. Stroke 1999; 30: 729–35

    PubMed  CAS  Google Scholar 

  145. Barker WH, Mullooly JP. Stroke in a defined elderly population 1967–1985: a less lethal and disabling but no less common disease. Stroke 1997; 28: 284–90

    PubMed  CAS  Google Scholar 

  146. Pohjasvaara T, Erkinjuntti T, Vataja R, et al. Dementia three months after stroke: baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort. Stroke 1997; 28: 785–92

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland

    Cinzia Sarti & Jaakko Tuomilehto

  2. Turku Community Health Centre, Turku, Finland

    Minna Kaarisalo

Authors
  1. Cinzia Sarti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Minna Kaarisalo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jaakko Tuomilehto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cinzia Sarti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sarti, C., Kaarisalo, M. & Tuomilehto, J. The Relationship Between Cholesterol and Stroke. Drugs & Aging 17, 33–51 (2000). https://doi.org/10.2165/00002512-200017010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200017010-00003

Keywords

Search

Navigation